1-12 of 12
John A. Davis
Close
Sort by
Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Warren Fiskus, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Antrix Jain, Anna Malovannaya, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Danielle Hammond, Patrick K. Reville, Jian Wang, Sanam Loghavi, Rwik Sen, Xinjia Ruan, Xiaoping Su, Lauren B. Flores, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2024) 143 (20): 2059–2072.
https://doi.org/10.1182/blood.2023022832
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1

Christopher Peter Mill, Warren C. Fiskus, John A. Davis, Kaberi Das, Christine E Birdwell, Tapan M. Kadia, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 5860–5861.
https://doi.org/10.1182/blood-2022-169584
Published: 2022
Journal Articles

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Kevin Philip, Noor Alhamadani, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Sanam Loghavi, Courtney D. DiNardo, Jesse Vargas, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 8807–8808.
https://doi.org/10.1182/blood-2022-165012
Published: 2022
Journal Articles

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 8819–8820.
https://doi.org/10.1182/blood-2022-164513
Published: 2022
Journal Articles

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression

Christine E Birdwell, Warren C. Fiskus, Tapan M. Kadia, Christopher Peter Mill, John A. Davis, Kaberi Das, Naval Daver, Courtney D. DiNardo, Koichi Takahashi, Koji Sasaki, Stephen Horrigan, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 493–494.
https://doi.org/10.1182/blood-2022-170715
Published: 2022
Journal Articles

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Noor Alhamadani, Kevin Philip, May Tan, Robert A Brown, Michael R Green, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 5980–5981.
https://doi.org/10.1182/blood-2022-168483
Published: 2022
Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla
Journal: Blood
Blood (2022) 139 (6): 907–921.
https://doi.org/10.1182/blood.2021013156
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

John A. Davis, Warren C. Fiskus, Naval Daver, Christopher Peter Mill, Christine Birdwell, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Mollie Leoni, Francis Burrows, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2021-149831
Published: 2021
Journal Articles

Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, John A. Davis, Arnold Salazar, Courtney D. DiNardo, Koichi Takahashi, Steve Horrigan, Tapan M. Kadia, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 3349.
https://doi.org/10.1182/blood-2021-154285
Published: 2021
Journal Articles

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Warren C. Fiskus, Christopher Peter Mill, Christine Birdwell, John A. Davis, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Gerard M. McGeehan, Naval Daver, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 3340.
https://doi.org/10.1182/blood-2021-152060
Published: 2021
Journal Articles

Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Christine Birdwell, Arnold Salazar, Arnold Salazar, John A. Davis, Koichi Takahashi, Joseph D. Khoury, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 1177.
https://doi.org/10.1182/blood-2021-152871
Published: 2021
Journal Articles

Clinical Validation of a Radiolabeled PF-4 Staph-a Binding Assay for Confirming Heparin Induced Thrombocytopenia

Hemasri Takala, MD, John A. Davis, BS, Kenneth A. Schwartz, MD
Journal: Blood
Blood (2015) 126 (23): 4655.
https://doi.org/10.1182/blood.V126.23.4655.4655
Published: 2015